Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review

• Published in: PloS one Vol. 17; no. 7; p. e0271908
• Main Authors: Jahangiri, Reza, Rezapour, Aziz, Malekzadeh, Reza, Olyaeemanesh, Alireza, Roshandel, Gholamreza, Motevalian, Seyed Abbas
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 28-07-2022; Public Library of Science (PLoS)
• Subjects: Antihypertensives; Cardiovascular disease; Cardiovascular diseases; Clinical trials; Cost analysis; Criteria; Disease prevention; Drug dosages; Drug therapy; Drug therapy, Combination; Economics; Evaluation; Heart diseases; Intervention; Literature reviews; Medical care, Cost of; Medicine and Health Sciences; Morbidity; Mortality; Patient outcomes; Physical Sciences; Population studies; Prevention; Purchasing power parity; Quality assessment; Quality control; Quality of life; Research and Analysis Methods; Social Sciences; Systematic review; Iran
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0271908

Background A significant proportion of cardiovascular disease (CVD) morbidity and mortality could be prevented via the population-based and cost-effective interventions. A fixed-dose combination treatment is known as the polypill for the primary and secondary prevention of CVD has come up in recent years. Purpose In order to provide recommendations for future economic evaluations, this systematic review aimed to review and assess the quality of published evidence on the cost-effectiveness of polypill in primary and secondary prevention of CVD, to identify the key drivers that impact the cost-effectiveness Methods A systematic review of literature, following the PRISMA guidelines, was undertaken in the electronic databases. Two researchers identified the relevant studies according to inclusion and exclusion criteria. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was used to quality assessment of included studies. ICERs value adjusted to 2020 United States Dollar using consumer price index (CPI) and purchasing power parity (PPP). Finally, data were summarized via a narrative synthesis. Results In total, 24 articles were identified based on the determined inclusion criteria. All studies met more than 50% of the CHEERS criteria. Adjusted incremental cost-effectiveness ratios varied from 24$ to 31000$(2020 US dollar) among the studies. The polypill resulted in the improved adherence and quality of life, at a price equal to or lower than multiple monotherapies. This price is typically below the commonly accepted thresholds or cost saving in both, primary and secondary prevention of CVD. The main identified cost-effectiveness drivers were the polypill price, adherence, age, CVD risk, and drug combination. Conclusions This systematic review found that the polypill seemed to be a cost-effective intervention in primary and secondary prevention of CVD. However, it is necessary to conduct more economic evaluation studies based on the long-term clinical trials with large populations. Also, studies should consider how the polypill interacts with other primary and secondary preventive strategies as a complementary health strategy.